PHILIPS

Atherectomy

Diverse patients. Versatile solutions.

Philips peripheral atherectomy portfolio



innovation you

Philips atherectomy portfolio



Phoenix strengths

- BTK calcium
- No volume requirements
- No capital equipment
- Mechanical solution

Combined strengths

- Mixed morphologies
- Full leg treatment
- Simple, single insertion
- Front cutting
- Maximal luminal gain[6]
- Directional control[6]

Laser strengths

- ISR[3]
- Step-by-Step CTO crossing[8]
- Thrombus
- 4F system*
- Level 1 clinical data[3]
- Non-mechanical solution

*available for Turbo-Elite

Safe

Phoenix atherectomy system: EASE trial[10]

Clinical concern	Phoenix atherectomy system solution	Safety data
Vessel injury	Front cutter clears tissue in a way that may help reduce potential trauma to the vessel	1.9% perforation 0.9% dissection*
Distal embolization**	Design of the Phoenix cutter head allows debulked material to be continuously captured	<1% distal embolization 0% use of distal protection

* grade C or greater
** requiring intervention

Turbo-Power and Turbo-Elite: Level 1 EXCITE trial[3]



Simple



Phoenix atherectomy system

Cut

Front cutter clears tissue in a way that may help reduce potential trauma to the vessel.[10]

Capture

Blades are designed for continuous capture of debulked material.

Clear

Archimedes screw clears debulked tissue.

Turbo-Power and Turbo-Elite

Light

Light pulse ablates mixed morphologies at molecular level, breaks molecular bonds, and debulks lesion.

Sound

Acoustic sound wave modifies hard plaque.

Cavitation bubble

Cavitation bubble expands and collapses, debulks mixed morphologies and enhances luminal gain.



Effective

Phoenix atherectomy system

- Phoenix catheters have been shown to effectively treat most peripheral vasculature. 1.8 mm and 2.2 mm (tracking) are suited for treating small vessels or highly stenosed lesions.
- 2.4 mm (tracking and deflecting) are suited for larger vessels or eccentric lesions.



Turbo-Power and Turbo-Elite

- Clinical superiority Level 1 clinical data proves it. The EXCITE ISR prospective randomized controlled trial included challenging real world cases with the longest lesions ever studied.

The Philips peripheral atherectomy portfolio: **a complementary solution**

Phoenix front cutting atherectomy system

Part number	Catheter size	Introducer size	Working length	Guidewire diameter
P18130K	1.8 mm tracking	5F	130 cm	0.014"
P18149K	1.8 mm tracking	5F	149 cm	0.014"
P22130K	2.2 mm tracking	6F	130 cm	0.014"
P22149K	2.2 mm tracking	6F	149 cm	0.014"
P24130K	2.4 mm tracking	7F	130 cm	0.014"
PD24127K	2.4 mm deflecting	7F	127 cm	0.014"

Turbo-Elite laser catheters

Part number	Catheter size	Introducer size	Working length	Guidewire diameter
410-152	0.9 mm	4F	150 cm	0.014"
414-151	1.4 mm	5F	150 cm	0.014"
417-152	1.7 mm	5F	150 cm	0.018"
420-006	2.0 mm	6F	150 cm	0.018"
423-001	2.3 mm	7F	120 cm	0.018"
425-011	2.5 mm	8F	110 cm	0.018"
423-135	2.3 mm	7F	125 cm	0.035"
425-135	2.5 mm	8F	112 cm	0.035"

Turbo-Power laser catheters

Part number	Catheter size	Introducer size	Working length	Guidewire diameter
423-050	2.3 mm	7F	120 cm	0.018"
420-050	2.0 mm	6F	150 cm	0.018"

Phoenix guidewires

Part number	Type	Diameter	Length	Tip	Style
PG14300LF	Silicone coated nitinol core	.014"	300 cm	Floppy	Light support
PG14300XF	Silicone coated stainless steel core	.014"	300 cm	Floppy	Extra support

References

1. ISR indication is only for laser atherectomy.
2. CTO indication is only for laser atherectomy.
3. Dippel et al. Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-stent Restenosis: Initial ISR Results (2015). JACC 8(1): 92-101.
4. Turbo-Power is indicated for laser atherectomy of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents, with adjunctive Percutaneous Transluminal Angioplasty (PTA).
5. Maximal luminal gain defined as 50% or greater stenosis reduction. Spectranetics Benchmark Study, unpublished data available upon request.
6. This feature is available for Turbo-Power laser atherectomy.
7. Zero contraindication only for peripheral laser atherectomy.
8. CTO crossing indication only for laser atherectomy.
9. Phoenix atherectomy device is indicated for vessels 2.5mm in diameter and above.
10. Davis, Thomas et al., Safety and effectiveness of the Phoenix Atherectomy System in lower extremity arteries: Early and midterm outcomes from the prospective multicenter EASE study. Vascular. September 27, 2017, DOI: 10.1177/1708538117712383.

©2018 Koninklijke Philips N.V. All rights reserved.
Some or all products manufactured by Spectranetics, a Philips company. Approved for external distribution.
D043798-00 112018

Philips
3721 Valley Centre Drive, Suite 500
San Diego, CA 92130 USA
www.philips.com/IGTdevices